Patents by Inventor François-Xavier Gendron

François-Xavier Gendron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11078152
    Abstract: The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(?) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: August 3, 2021
    Assignee: Universite de Rouen
    Inventors: Gérard Coquerel, Julien Mahieux, François-Xavier Gendron
  • Publication number: 20190345098
    Abstract: The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(?) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).
    Type: Application
    Filed: July 20, 2017
    Publication date: November 14, 2019
    Applicant: Universite de Rouen
    Inventors: Gérard Coquerel, Julien Mahieux, François-Xavier Gendron